Allergen Testing (serum and skin) coverage
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
BCBSNC policy on medical coverage and reimbursement guidelines for allergen testing (skin and in‑vitro serum IgE tests) for commercial members; defines covered indications, limits, and tests considered not covered.
Coverage criteria edited for clarity; reimbursement is allowed for specific IgE in‑vitro allergy testing (up to 40 allergen specific antibodies per year) when limited to allergens chosen based on history, exam, and environment.
Reimbursement is not allowed for specific IgE in‑vitro allergy testing when performed on the same day as skin prick testing.
Not covered section consolidated and clarified to disallow basophil activation flow cytometry testing and in‑vitro testing of non-IgE immunoglobulins for individuals with signs or symptoms of allergies.
Added CPT/procedure code 95004 to Billing/Coding section.
Coverage Criteria and Limitations
When Allergen Testing is covered
Covered when the following conditions are met:
[chunk 5]
[chunk 5]
When Allergen Testing is not covered
The following tests/uses are explicitly not reimbursed:
[chunk 6]
[chunk 6]
[chunk 6, chunk 12]
[chunk 6, chunk 13]
[chunk 6]
[chunk 6]
Medically necessary testing criteria
Covered when testing is clinically indicated and guided by history/exam
AAAI/ACAAI and WAO guidance; see chunks 26 and 35
AAAI/ACAAI and NIAID guidance; see chunks 26 and 40
NIAID, WAO, and specialty evidence cited; see chunks 21, 40, 49
Appropriate use criteria for allergen testing
Tests and modalities are appropriate when guided by an allergy-focused history and when results will affect management or are needed for specialty therapy decision-making.
Supported by WAO, NIAID, AAP, International Consensus; see chunks 36, 40, 41, 45, 53
NIAID and NICE guidance; see chunks 40 and 53
NIAID and AAP recommendations; see chunks 41 and 42
WAO/EAACI/NICE support selective use; see chunks 35, 51, 53
National Academies and EAACI caution; see chunks 49 and 51
Choosing Wisely and specialty guidance; see chunks 29 and 38
When Covered
Covered when ALL of the following are met
Revised language clarifies limitation; increase to 40 allergens effective 10/15/24 and reaffirmed 5/27/26.
When Not Covered
Not covered (Reimbursement is not allowed for):
Policy consolidations and prohibitions documented across updates; see chunks 70 and 69.
Added 5/27/26 with notification effective 8/5/26; see chunk 71.
The policy excludes reimbursement for several proprietary and emerging tests that lack sufficient reproducibility or proven clinical utility. Examples explicitly listed include the Antigen Leukocyte Antibody Test (ALCAT) and in‑vitro bead‑based epitope assays such as VeriMAP Peanut Dx. The policy also identifies broad, non‑specific multi‑analyte panels (for example, large IgG/IgE food panels and microarray‑style assays) as not reimbursed when they do not have validated clinical correlation.
Routine broad screening or indiscriminate battery testing is discouraged and may not be reimbursed. Specialty guidance recommends selecting allergens and tests based on the patient’s history, physical exam, environment and exposures rather than ordering wide, non‑targeted IgE panels or routine retesting without a new clinical presentation.
Skin prick testing is not routinely indicated for conditions that are unlikely to reflect IgE‑mediated mechanisms. The policy and guideline sources note that SPT should not be used for suspected food intolerance, chronic urticaria without allergic features, non‑specific cutaneous rashes without atopic features, or other non‑allergic presentations unless the history clearly implicates an IgE‑mediated trigger.
Royal College of Pathologists guidance emphasizes that allergy testing is not indicated for isolated, randomly occurring urticaria without a consistent, reproducible trigger. Testing should be limited to cases where clinical features meet criteria consistent with an IgE‑mediated mechanism and where results will influence management.
The policy treats certain assays as research or not sufficiently standardized for routine clinical use. Basophil activation flow cytometry testing (BAT) is discussed as promising but currently limited by lack of standardization and therefore described as not established for routine practice. Histamine release assays and other nonstandardized proprietary panels are likewise considered investigational or lacking adequate clinical validation.
The policy states that IgG and IgG‑subclass testing for food allergy is not clinically relevant and should not be performed for allergy diagnosis. Total serum IgE is noted to have only modest clinical value as a screening measure; the policy describes specific situations where total IgE measurement may be appropriate (for example, in moderate‑to‑severe asthma or suspected ABPA and for certain monitoring contexts) rather than as a routine diagnostic for food allergy.
Specific IgG testing to panels of foods and routine use of BAT or other non‑standardized assays for food allergy diagnosis are not supported by guideline bodies cited in the policy. Choosing Wisely and national expert reviews recommend against using IgG panels and caution that BAT remains a research tool pending further validation, so routine use for food allergy diagnosis is not supported.
The policy consolidates multiple exclusions into a clear Not Covered section: reimbursement is not allowed for in‑vitro testing of non‑specific immunoglobulins (IgG/IgA/IgM/IgD) for allergy evaluation, basophil activation flow cytometry testing, proprietary tests lacking validation (eg, ALCAT, VeriMAP), qualitative multi‑allergen screens that do not identify specific allergens, and for specific IgE in‑vitro testing performed the same day as skin prick testing.
Billing and Coding
| No codes listed |
| 82784 | Immunoassay for specific IgE |
| 82785 | Immunoassay for specific IgE |
| 82787 | Immunoassay for specific IgE |
| 83516 | Allergen-related immunoassay (removed earlier from policy but listed here in applicable codes) |
| 86001 | Allergen-specific IgE; quantitative |
| 86003 | Allergen-specific IgE; multiple allergen screen |
| 86005 | Allergen-specific IgE |
| 86008 | Allergen-specific IgE |
| 88184 | Patch test interpretation |
| 88185 | Patch test interpretation |
Provider Actions, Documentation, and Prior Authorization
Prior authorization
No explicit prior authorization requirements are stated within this policy document for allergen testing.
History-guided testing; use in‑vitro when skin testing unsafe
Select allergens and test modality based on the patient’s history, physical examination, environment/region, and exposure risk; use in‑vitro specific IgE testing when skin testing is unsafe or poses a high anaphylaxis risk.
- Choose tests guided by patient age, history, environment, occupation, and activities per AAAAI/ACAAI.
- Prefer skin testing when safe; use in‑vitro testing for widespread skin disease, interfering medications, uncooperative patients, or high anaphylaxis risk.
Billing codes listed — prior auth/documentation may be required
Applicable service codes are listed in the policy, but inclusion does not guarantee reimbursement; prior authorization or additional documentation may be required per BCBSNC administrative policies.
Applicable service codes — verify reimbursement/prior auth
The policy lists specific procedure codes that may apply to allergen testing; inclusion only signals applicability — providers should verify reimbursement and prior authorization requirements with BCBSNC.
- Codes shown in the policy do not guarantee payment; check BCBSNC administrative guidance before billing.
Preferred testing modality
Skin testing is described as the preferred, rapid, sensitive, and cost‑effective modality for detecting IgE‑mediated disease and is generally the primary approach unless contraindicated.
- Procedure is brief (<1 hour) with minimal discomfort and is the preferred method when safe and feasible.
Suggested sequential testing for peanut
For evaluation of peanut allergy consider component testing (Ara h2) and SPT or sIgE; in select cases with equivocal SPT or Ara h2‑sIgE, perform BAT to reduce need for oral food challenge.
- Ara h2 may be preferred when a single diagnostic test is used due to superior diagnostic accuracy but has lower sensitivity than SPT or sIgE.
- BAT can be used after equivocal SPT/Ara h2‑sIgE and has been shown in a study to reduce required OFCs substantially.
IgE testing for Xolair dosing
Measure total serum IgE prior to initiation of omalizumab (Xolair); total IgE level and body weight determine dose and dosing frequency, and total IgE should be obtained before starting therapy.
- Do not use IgE levels obtained during Xolair treatment to guide dosing (levels remain elevated during and up to one year after discontinuation).
Clinical selection and documentation
Choose allergens and specific tests based on an individual’s history, physical exam, and environment; coverage is provided when testing meets the policy’s clinical criteria (e.g., history‑guided selection and limits such as up to 40 allergen‑specific antibodies per year).
- Limit in‑vitro specific IgE testing to allergens selected from history/exam/environment; reimbursement allowed up to 40 allergen‑specific antibodies per year when criteria met.
Clinical justification and documentation
Document the clinical history, focused physical examination, and clinical rationale for the allergens and tests selected (history‑guided selection per AAAAI/ACAAI and related recommendations).
- For perioperative anaphylaxis, document timing, suspected agents, and rationale if testing is delayed or referred.
- Record why SPT or in‑vitro testing was chosen given patient‑specific factors (eg, contraindications to skin testing).
Medical records for medical necessity
BCBSNC may request medical records to determine medical necessity; letters of support alone are not sufficient unless they contain all specific information needed for the determination.
- When records are requested include the clinical history, physical examination findings, rationale for test selection, and any relevant prior testing or therapy.
Records required for medical necessity review
When BCBSNC requests records for a medical necessity review, include all specific information needed to determine necessity—history, exam findings, rationale for test selection, timing of symptoms, and any prior tests or results; letters alone are insufficient unless they contain these details.
- Provide documentation of symptoms that prompted testing, environmental/occupational exposures, and how results will affect management.
Tests that trigger noncoverage
Claims may be denied when tests explicitly not allowed by the policy are performed, including basophil activation flow cytometry testing, in‑vitro testing of IgG/IgA/IgM/IgD for allergy evaluation, the ALCAT test, bead‑based epitope assays (e.g., VeriMAP), qualitative multi‑allergen screens that do not identify specific allergens, and specific IgE in‑vitro testing performed on the same day as skin prick testing.
- Avoid submitting claims for these disallowed tests to prevent denial of reimbursement.
Indiscriminate testing risk
Performing indiscriminate or history‑unguided testing (for example, broad IgE panels or routine broad screening without a new clinical presentation) is discouraged by specialty guidance and may risk non‑coverage or be considered low‑value.
- Select tests targeted to the patient’s symptoms, history, and exposure rather than ordering broad screening panels.
Documentation-triggered denials
Inclusion of a billing code in the policy does not guarantee reimbursement; BCBSNC may request medical records to determine medical necessity and lack of required documentation can trigger denial.
- Ensure clinical documentation supports the billed test and be prepared to provide records when requested.
Medical record documentation may be requested
BCBSNC may request medical records for determination of medical necessity; inclusion of a code in the policy does not guarantee reimbursement.
- Maintain complete records (history, exam, rationale, prior results) to support medical necessity if requested.
Clinical Background and Evidence Summary
Allergic disease arises from inappropriate immune responses and includes both IgE‑mediated (type I) and T cell–mediated (type IV) mechanisms. Serum specific IgE testing detects allergen‑specific antibodies and indicates sensitization but does not by itself confirm clinical reactivity; clinical history, examination, and, when necessary, supervised challenge testing are required to establish true allergy. Skin testing is described as a rapid, sensitive, and cost‑effective modality for detecting IgE‑mediated disease, while patch testing is preferred for delayed, T cell–mediated reactions.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.